Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

nsing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
(Date:9/18/2014)...  U.S. biotech company Kultevat has strengthened ... technology developed by the Donald Danforth Plant Science ... for applications in production of natural rubber in ... developed under the direction of Roger Beachy , ... of the Danforth Plant Science Center, and is used ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a ... the early detection of diseases and personalized health ... a agreement allowing Centocor Research & Development, Inc. ... biomarker program. Additional terms of the agreement were ...
... Hovione announced today,that it has agreed with Pfizer to ... This site manufactures,intermediates for Lipitor active pharmaceutical ingredient. , ... had a number of owners starting in 1984 with ... and now Hovione. Over,the last 10 years Pfizer has ...
... McCulley/Cuppan announced today the launch of a new series of web-based ... The web delivered "short" courses are one hour in duration and ... writing skills. , ... Salt Lake City, Utah (PRWEB) ...
Cached Biology Technology:GeneNews provides Centocor access to its osteoarthritis program 2Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 2McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 3
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... COLUMBUS, Ohio - For the first time, researchers have found ... therapy agent directly into a single living cell without a ... therapeutic biomolecules through a tiny channel and into a cell ... and his colleagues at Ohio State University describe the technique ...
... terrorized its plant-eating neighbours in South America was a lot ... found. Carnotaurus was a seven-metre-long predator with ... student Scott Persons says made it one of the fastest ... tail bones of Carnotaurus showed its caudofemoralis muscle ...
... , New York, NY (October 14, 2011) Researchers at ... uncovered a vast new gene regulatory network in mammalian cells ... The studies appear in today,s online edition of Cell ... a missing piece in the puzzle of cell regulation and ...
Cached Biology News:Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3Vast hidden network regulates gene expression in cancer 2Vast hidden network regulates gene expression in cancer 3
...
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Biology Products: